Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy

David Aguilar; Samuel Z. Goldhaber; Daniel J. Gans; Andrew S. Levey; Jerome G. Porush; Julia B. Lewis; Jean Lucien Rouleau; Tomas Berl; Edmund J. Lewis; Marc A. Pfeffer

doi:10.1016/j.amjcard.2004.04.028

Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy

David Aguilar, Samuel Z. Goldhaber, Daniel J. Gans, Andrew S. Levey, Jerome G. Porush, Julia B. Lewis, Jean Lucien Rouleau, Tomas Berl, Edmund J. Lewis, Marc A. Pfeffer

Internal Medicine

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.

Original language	English
Pages (from-to)	337-339
Number of pages	3
Journal	American Journal of Cardiology
Volume	94
Issue number	3
DOIs	https://doi.org/10.1016/j.amjcard.2004.04.028
State	Published - Aug 1 2004

Bibliographical note

Funding Information:
The Irbesartan Diabetic Nephropathy Trial was sponsored with grant support by Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey, and Sanofi-Synthelabo, Inc., New York, New York.

Funding

The Irbesartan Diabetic Nephropathy Trial was sponsored with grant support by Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey, and Sanofi-Synthelabo, Inc., New York, New York.

Funders	Funder number
Bristol-Myers Squibb Pharmaceutical Research Institute
Sanofi-Synthelabo, Inc., New York, New York

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.amjcard.2004.04.028

Cite this

Aguilar, D., Goldhaber, S. Z., Gans, D. J., Levey, A. S., Porush, J. G., Lewis, J. B., Rouleau, J. L., Berl, T., Lewis, E. J., & Pfeffer, M. A. (2004). Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. American Journal of Cardiology, 94(3), 337-339. https://doi.org/10.1016/j.amjcard.2004.04.028

@article{5cef35a59beb46b0801c0030b668f8c9,

title = "Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy",

abstract = "During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14\% of all first nonfatal MIs.",

author = "David Aguilar and Goldhaber, \{Samuel Z.\} and Gans, \{Daniel J.\} and Levey, \{Andrew S.\} and Porush, \{Jerome G.\} and Lewis, \{Julia B.\} and Rouleau, \{Jean Lucien\} and Tomas Berl and Lewis, \{Edmund J.\} and Pfeffer, \{Marc A.\}",

note = "Funding Information: The Irbesartan Diabetic Nephropathy Trial was sponsored with grant support by Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey, and Sanofi-Synthelabo, Inc., New York, New York. ",

year = "2004",

month = aug,

day = "1",

doi = "10.1016/j.amjcard.2004.04.028",

language = "English",

volume = "94",

pages = "337--339",

number = "3",

}

TY - JOUR

T1 - Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy

AU - Aguilar, David

AU - Goldhaber, Samuel Z.

AU - Gans, Daniel J.

AU - Levey, Andrew S.

AU - Porush, Jerome G.

AU - Lewis, Julia B.

AU - Rouleau, Jean Lucien

AU - Berl, Tomas

AU - Lewis, Edmund J.

AU - Pfeffer, Marc A.

N1 - Funding Information: The Irbesartan Diabetic Nephropathy Trial was sponsored with grant support by Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey, and Sanofi-Synthelabo, Inc., New York, New York.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.

AB - During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.

UR - http://www.scopus.com/inward/record.url?scp=3242705235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242705235&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.04.028

DO - 10.1016/j.amjcard.2004.04.028

M3 - Article

C2 - 15276098

AN - SCOPUS:3242705235

SN - 0002-9149

VL - 94

SP - 337

EP - 339

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 3

ER -

Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this